Peer-reviewed veterinary case report
Canine indolent lymphoma types and survival after treatment
By Flood-Knapik, K E et al.·Published in Veterinary and comparative oncology·2013·Matthew J. Ryan Veterinary Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma.
- Species:
- dog
Plain-English summary
A group of 75 dogs diagnosed with indolent lymphoma, a type of cancer that grows slowly, was studied to understand its characteristics and treatment outcomes. The most common subtype found was T-zone lymphoma, which had an average survival time of about 33.5 months. Dogs treated with a combination of chlorambucil and prednisone did not have a defined survival time, while those receiving CHOP-based chemotherapy lived an average of 21.6 months. Overall, these dogs had a long average survival time of 4.4 years, indicating that indolent lymphoma is a less aggressive form of cancer.
People also search for: dog indolent lymphoma treatment · T-zone lymphoma in dogs · chlorambucil vs CHOP chemotherapy for dogs
Abstract
Indolent lymphoma comprises up to 29% of all canine lymphoma; however, limited information exists regarding the subtypes and biological behaviour. This retrospective study describes the clinical characteristics, histopathological and immunohistochemical features, treatment, outcome and prognostic factors for 75 dogs with indolent lymphoma. WHO histopathological classification and immunohistochemistry (IHC) for CD79a, CD3, Ki67 and P-glycoprotein (P-gp) was performed. The most common histopathological subtype was T-zone, 61.7%, (MST 33.5 months), followed by marginal zone, 25%, (MST 21.2 months), P = 0.542. The addition of IHC to preliminary histopathological classification resulted in a revised diagnosis in 20.4% of cases. The use of systemic treatment did not influence survival, P = 0.065. Dogs treated with chlorambucil and prednisone did not reach a MST, compared with a MST of 21.6 months with CHOP-based chemotherapy, P = 0.057. The overall MST of 4.4 years confirms that this is indeed an indolent disease. However, the effect of systemic treatment must be determined through prospective trials.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22296667/